Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmacia

Full company profile

uuid003bfmy

Namestring
Pharmacia
Websiteurl
pharmacia.com
Company typeenum
Private
Founded yearint
1837
Descriptiontext

Pharmacia Corporation historically developed, manufactured, and marketed prescription pharmaceutical products and services, with claimed operations dating to 1837 and a stated historical headcount of more than 10,000 employees. The entity was based in Peapack, New Jersey, United States. Documented historical leadership included Robert Shapiro as Chairman of the Board of Directors and Göran Ando as Executive Vice President. Pharmacia was acquired by Pfizer in 2003 per the ownership commentary in the source data, at which point the standalone corporate entity effectively ceased to exist as an independent operator.

The current operating status of any entity continuing to use the Pharmacia name is unclear from the available source material. The corporate domain pharmacia.com is currently listed as a parked page for sale on GoDaddy Auctions, with no substantive company information, product portfolio, customer base, management team details, certifications, partnerships, regulatory actions, or financial disclosures recorded. The primary source explicitly states that the current status and ownership of any remaining entities under the Pharmacia name cannot be determined from the provided sources, and that the domain is currently a parked GoDaddy Auctions page. All enumerated fields for products, customers, revenue, headcount, partnerships, and active operations are empty in the detailed company data extract.

Short descriptiontext

Pharmacia historically developed, manufactured, and marketed prescription pharmaceutical products, based in Peapack, New Jersey, with operations claimed since 1837. Current operating status is unclear, as the primary domain pharmacia.com is listed as a parked page for sale on GoDaddy Auctions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKalamazoo, United States
HQ citystring
Kalamazoo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
prescription pharmaceuticals, drug manufacturing, pharmaceutical research, human health products, prescription medicines
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Prescription Pharmaceuticals
Social media profiles1 record
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pharmacia develops, manufactures, and markets prescription pharmaceutical products and services for human health applications. The company's activities span drug discovery, formulation, industrial-scale manufacturing, and the commercialization of prescription medicines, supported by a workforce of more than 10,000 employees.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GSK is a global branded pharmaceutical company with R&D, manufacturing, and commercial operations spanning primary care and specialty therapeutics, making it a direct functional comparable in business model and category.

TypeBroad incumbent
Description

AbbVie is a research-driven, integrated biopharmaceutical company that develops, manufactures, and markets prescription drugs globally, sharing the same R&D-to-commercial model as the described Pharmacia business.

TypeBroad incumbent
Description

Merck is a US-headquartered, vertically integrated prescription pharmaceutical developer and manufacturer with a primary-care and general-medicine portfolio, directly comparable in business model to the stated Pharmacia activities.

TypeBroad incumbent
Description

Novartis is a global developer, manufacturer, and marketer of branded prescription pharmaceuticals, with a portfolio structure (innovative medicines) directly comparable to the activities described for Pharmacia.

TypeBroad incumbent
Description

Eli Lilly is a major US-based branded pharmaceutical manufacturer with a portfolio spanning primary care and specialty therapeutics, directly comparable in development, manufacturing, and commercial scope.

TypeBroad incumbent
Description

AstraZeneca is a global, science-led prescription pharmaceutical company that develops, manufactures, and commercializes branded drugs across primary care and specialty therapy areas, mirroring the integrated business model described.

TypeBroad incumbent
Description

Pfizer acquired the historical Pharmacia Corporation in 2003, making it the most directly comparable incumbent: a global developer, manufacturer, and marketer of prescription pharmaceuticals across primary care and specialty therapeutic areas.

TypeBroad incumbent
Description

Roche is a vertically integrated pharmaceutical developer and manufacturer with both branded and biologic products, comparable in scope and value chain to a full-stack prescription drug operator like Pharmacia historically was.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb is a US-headquartered branded pharmaceutical manufacturer with integrated discovery, development, manufacturing, and commercialization capabilities across primary and specialty care.

TypeBroad incumbent
Description

Johnson & Johnson's pharmaceutical segment (Janssen) develops, manufactures, and markets branded prescription medicines globally, making it a broad incumbent peer in the same prescription drug value chain.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmacia

Prescription Pharmaceuticalspharmacia.com

Pharmacia historically developed, manufactured, and marketed prescription pharmaceutical products, based in Peapack, New Jersey, with operations claimed since 1837. Current operating status is unclear, as the primary domain pharmacia.com is listed as a parked page for sale on GoDaddy Auctions.

What Pharmacia does

Pharmacia Corporation historically developed, manufactured, and marketed prescription pharmaceutical products and services, with claimed operations dating to 1837 and a stated historical headcount of more than 10,000 employees. The entity was based in Peapack, New Jersey, United States. Documented historical leadership included Robert Shapiro as Chairman of the Board of Directors and Göran Ando as Executive Vice President. Pharmacia was acquired by Pfizer in 2003 per the ownership commentary in the source data, at which point the standalone corporate entity effectively ceased to exist as an independent operator.

The current operating status of any entity continuing to use the Pharmacia name is unclear from the available source material. The corporate domain pharmacia.com is currently listed as a parked page for sale on GoDaddy Auctions, with no substantive company information, product portfolio, customer base, management team details, certifications, partnerships, regulatory actions, or financial disclosures recorded. The primary source explicitly states that the current status and ownership of any remaining entities under the Pharmacia name cannot be determined from the provided sources, and that the domain is currently a parked GoDaddy Auctions page. All enumerated fields for products, customers, revenue, headcount, partnerships, and active operations are empty in the detailed company data extract.

Pharmacia firmographics

Firmographics
Name
Pharmacia
Website
https://pharmacia.com
Company type
Private
Founded year
1837
Operating status
Operating
Headcount range
51–100 employees
Short description
Pharmacia historically developed, manufactured, and marketed prescription pharmaceutical products, based in Peapack, New Jersey, with operations claimed since 1837. Current operating status is unclear, as the primary domain pharmacia.com is listed as a parked page for sale on GoDaddy Auctions.
Ownership category
akta.pro rank

Pharmacia industry classification

Industry
Product category
Prescription Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Prescription pharmaceuticals
  • Drug manufacturing
  • Pharmaceutical research
  • Human health products
  • Prescription medicines

Where Pharmacia is headquartered

Location

Headquarters

HQ city
Kalamazoo
HQ country
United States
HQ region
North America

Markets served

Pharmacia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Pharmacia product offering

Product offering

Core offering

Pharmacia develops, manufactures, and markets prescription pharmaceutical products and services for human health applications. The company's activities span drug discovery, formulation, industrial-scale manufacturing, and the commercialization of prescription medicines, supported by a workforce of more than 10,000 employees.

Differentiator

Problem solved

Functional benefit

Companies that use Pharmacia

Customer profile

Ideal customer profiles1 record

Pharmacia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Pharmacia partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Pharmacia competitors and assessment

Company assessment

Broad incumbents

  • GlaxoSmithKline: GSK is a global branded pharmaceutical company with R&D, manufacturing, and commercial operations spanning primary care and specialty therapeutics, making it a direct functional comparable in business model and category.
  • AbbVie: AbbVie is a research-driven, integrated biopharmaceutical company that develops, manufactures, and markets prescription drugs globally, sharing the same R&D-to-commercial model as the described Pharmacia business.
  • Merck & Co. Merck is a US-headquartered, vertically integrated prescription pharmaceutical developer and manufacturer with a primary-care and general-medicine portfolio, directly comparable in business model to the stated Pharmacia activities.
  • Novartis: Novartis is a global developer, manufacturer, and marketer of branded prescription pharmaceuticals, with a portfolio structure (innovative medicines) directly comparable to the activities described for Pharmacia.
  • Eli Lilly and Company: Eli Lilly is a major US-based branded pharmaceutical manufacturer with a portfolio spanning primary care and specialty therapeutics, directly comparable in development, manufacturing, and commercial scope.
  • AstraZeneca: AstraZeneca is a global, science-led prescription pharmaceutical company that develops, manufactures, and commercializes branded drugs across primary care and specialty therapy areas, mirroring the integrated business model described.
  • Pfizer: Pfizer acquired the historical Pharmacia Corporation in 2003, making it the most directly comparable incumbent: a global developer, manufacturer, and marketer of prescription pharmaceuticals across primary care and specialty therapeutic areas.
  • Roche: Roche is a vertically integrated pharmaceutical developer and manufacturer with both branded and biologic products, comparable in scope and value chain to a full-stack prescription drug operator like Pharmacia historically was.
  • Bristol-Myers Squibb: Bristol-Myers Squibb is a US-headquartered branded pharmaceutical manufacturer with integrated discovery, development, manufacturing, and commercialization capabilities across primary and specialty care.
  • Johnson & Johnson: Johnson & Johnson's pharmaceutical segment (Janssen) develops, manufactures, and markets branded prescription medicines globally, making it a broad incumbent peer in the same prescription drug value chain.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Pharmacia social profiles

Digital presence

Pharmacia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmacia leadership team

Management profile

Number of profiles

Profiles2 records

Pharmacia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmacia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmacia

What does Pharmacia do?

Pharmacia develops, manufactures, and markets prescription pharmaceutical products and services for human health applications. The company's activities span drug discovery, formulation, industrial-scale manufacturing, and the commercialization of prescription medicines, supported by a workforce of more than 10,000 employees.

When was Pharmacia founded?

Pharmacia was founded in 1837. It employs 51 to 100 people.

Where is Pharmacia based?

Pharmacia is headquartered in Kalamazoo, United States, in the North America region.

Who are Pharmacia's main competitors?

Broad incumbents on record are GlaxoSmithKline, AbbVie, Merck & Co., Novartis, Eli Lilly and Company, AstraZeneca, Pfizer, Roche, Bristol-Myers Squibb and Johnson & Johnson.

Does Pharmacia have an API?

No public API is recorded for Pharmacia.

What industry is Pharmacia in?

Pharmacia's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MLivePfizer warehouse part of $147M investment in PortagePfizer expanded its Portage, Michigan manufacturing plant by 98,500 square feet as part of a $147 million investment, adding a new warehouse and distribution operation. The facility will handle 60% more finished products and is expected to operate 24/7 by March. Pfizer plans to invest $190 million annually in the site for several years.PR Newswire APACMicuRx Reports Positive Top-Line Results From Phase 2 US Clinical Trial For Novel Antibiotic MRX-IMicuRx reported positive top-line results from its Phase 2 US trial of MRX-I, an oral oxazolidinone antibiotic for drug-resistant bacteria. The study showed 90% early clinical response in the MRX-I group versus 87.5% in the linezolid group, with no myelosuppression. The company also appointed Barry Hafkin as chief medical officer.PR NewswireMicuRx Reports Positive Top-Line Results From Phase 2 US Clinical Trial For Novel Antibiotic MRX-IMicuRx reported positive top-line results from its Phase 2 US trial of MRX-I, an oral oxazolidinone antibiotic for drug-resistant bacteria. The study showed 90% early clinical response in the MRX-I group versus 87.5% in the linezolid group, with no myelosuppression. The company also appointed Barry Hafkin as chief medical officer.PR NewswireChina's Parecoxib Market Investigation Report 2015Research and Markets announced a market investigation report on China's Parecoxib market. Parecoxib sales rose from under CNY 20 million in 2008 to over CNY 200 million in 2014, with a CAGR of 54.70%. Upjohn held a monopoly with CNY 204 million in 2014, and local competition is expected in the next few years.PR NewswireChina's Methylprednisolone Investigation Report 2010-2019Research and Markets announced a report on China's methylprednisolone market, 2010-2019. Sales value rose from under CNY 90 million in 2005 to CNY 295 million in 2014, with Pfizer Manufacturing Belgium holding 43.7% of sales value in 2014. The market is expected to keep growing.GlobeNewswireOrion discontinues deramciclane studies in GAD due to lack of efficacy in Phase 3Orion Pharma and Pharmacia Corporation discontinued deramciclane's clinical trials for generalized anxiety disorder after Phase 3 studies failed to show statistically significant efficacy. The compound showed anxiolytic effects in Phase 2 but not in Phase 3. Orion may evaluate other indications for the compound.GlobeNewswireOrion to Receive Milestone Payment from Pharmacia Under Deramciclane Collaboration AgreementOrion Pharma will receive a $5 million milestone payment from Pharmacia Corporation in Q4 2002 for its collaboration on deramciclane for generalized anxiety disorder. The drug is in Phase III clinical development in Europe and the U.S., with full results expected in early 2003.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: ALERT: Target Update on Calpine, Novellus Systems, Network Appliance, Pharmacia Corporation, FinisarEquityOutlook.Com issued stock ratings for Calpine, Novellus Systems, Network Appliance, Pharmacia, and Finisar, assigning Outperform to Calpine and Novellus, and Underperform to the others. The ratings are based on a proprietary technical analysis system that assesses short-term price movement versus the S&P 500, not long-term views.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: New Ratings on Pharmacia Corporation, Finisar Corporation, Applied Micro Circuits, AES Corporation, Apple Computer IncEquityOutlook.Com issued new stock ratings on Pharmacia, Finisar, Applied Micro Circuits, AES, and Apple, assigning Underperform, Outperform, or Underperform labels. The ratings are based on a proprietary technical analysis system that assesses short-term price movement versus the S&P 500, not a long-term view.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: ALERT -- Rating Change for Electronic Data Systems, Pharmacia Corporation, Kmart Corp, Halliburton Co, Riverstone NetworkEquityOutlook.Com issued short-term stock ratings for five companies, including Electronic Data Systems, Pharmacia, Kmart, Halliburton, and Riverstone Network. The ratings range from underperform to outperform, with a proprietary technical analysis system. The company states these ratings reflect short-term price movement versus the S&P 500.